Evaluation of Meibomian Glands in Cutaneous Rosacea

Purpose: To evaluate the tear parameters, meibomian glands and lid margin and tarsal conjunctival impression cytology in patients with conjunctivochalasis (CCH). Methods: The study included 57 patients diagnosed with CCH and 35 healthy volunteers. Tear break-up time (TBUT) was measured and Schirmer test was performed. Meibomian gland morphologies, dropout rates, and meiboscores were evaluated using meibography. Finally, impression cytology samples were taken by pressing the impression filters on the lower lid margin and lower tarsal conjunctiva. The samples were evaluated according to the Nelson grading system. Results: Schirmer test was longer and TBUT was shorter in the study group ( p = 0.035 and p < 0.001, respectively). The median of meibomian gland dropout rate was 33.45% (Interquartile range [IQR]; 23.17%–49.75%) and 18.80% (IQR; 12.35%–26.50%) in the study and control groups, respectively ( p < 0.001). There was no significant difference in terms of lid-margin cytology between the two groups ( p = 0.481). In tarsal conjunctiva cytology, the median value of Nelson grade of the study group was 2 (IQR; 1–2) and that of the control group was 1 (IQR; 1–2) ( p = 0.040). When Nelson grade-2 and above was accepted as the pathological limit, it was found that 27.5% of the study group and 15.2% of the control group showed pathological findings ( p = 0.204). Conclusions: In patients with CCH, damage occurs in the tarsal conjunctiva with the effects of redundant conjunctival folds. In these patients, atrophy occurs in the meibomian glands and tear stability is impaired. Therefore, CCH should not be overlooked in clinical practice.

Download Full-text

Lipidomic analysis of meibomian glands from type-1 diabetes mouse model and preliminary studies of potential mechanism

Experimental Eye Research ◽

10.1016/j.exer.2021.108710 ◽

2021 ◽

pp. 108710

Author(s):

Huifeng Wang ◽

Qingjun Zhou ◽

Luqin Wan ◽

Menglong Guo ◽

Chen Chen ◽

...

Keyword(s):

Type 1 Diabetes ◽

Mouse Model ◽

Potential Mechanism ◽

Lipidomic Analysis ◽

Meibomian Glands ◽

Diabetes Mouse

Download Full-text

Tear lipid layer structure and stability following expression of the meibomian glands

Ophthalmic and Physiological Optics ◽

10.1016/0275-5408(95)00071-k ◽

1995 ◽

Vol 15 (6) ◽

pp. 569-574 ◽

Cited By ~ 67

Author(s):

J Craig

Keyword(s):

Layer Structure ◽

Lipid Layer ◽

Structure And Stability ◽

Meibomian Glands

Download Full-text

A Spatula of Plastic Material for Expressing Meibomian Glands*†

American Journal of Ophthalmology ◽

10.1016/s0002-9394(42)90911-5 ◽

1942 ◽

Vol 25 (4) ◽

pp. 455-456

Author(s):

Conrad Berens

Keyword(s):

Plastic Material ◽

Meibomian Glands

Download Full-text

Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients

10.21203/rs.3.rs-468283/v1 ◽

2021 ◽

Author(s):

Siyuan Li ◽

Ke Yang ◽

Jingyi Wang ◽

Shang Li ◽

Lei Zhu ◽

...

Keyword(s):

Group Treatment ◽

Controlled Trial ◽

Anterior Segment ◽

Meibomian Gland ◽

Chinese Patients ◽

Meibomian Gland Dysfunction ◽

Controlled Clinical Trial ◽

Randomized Controlled ◽

Meibomian Glands ◽

Thermostatic Device

Abstract BackgroundAs a chronic disease, meibomian gland dysfunction (MGD) which causes excessive evaporation of tears by changing the tear film composition, is considered a leading cause of dry eye. Although a variety of physical therapy equipment, there is currently no economical and effective treatment for MGD. The aim of this study was to evaluate the effectiveness and safety of the MiBoFlo Thermoflo® (Mibo Medical, Dallas, TX, USA), a new thermostatic device, on both objective symptoms and subjective signs in Chinese MGD patients.MethodsThis was a prospective, randomized, controlled clinical trial. 108 eyes of 54 MGD patients in Beijing Tongren Hospital were recruited and randomized 1:1 to MiBoFlo (n = 54 eyes) or LipiFlow® (TearScience, Morrisville, NC, USA) (n = 54 eyes) treatment group. In the MiBoFlo group, treatment for each eye took 10 minutes and proceeded every two weeks for a total of three times. Patients in the LipiFlow group received a single 12-minute treatment. Main Outcome Measures: The primary outcomes include changes in Ocular Surface Disease Index (OSDI) score, Meibomian Glands Yielding Liquid Secretion (MGYLS) score and Meibomian Glands Secretion (MGS) score from baseline to 2 months. The secondary outcomes include Tear Meniscus Height (TMH), Non-invasive Keratograph Break-up Time (NIKBUT), Corneal Fluorescein Staining (CFS) and Meibomian Glands (MG) loss from baseline to 2 months. Safety outcomes include visual acuity (VA), intraocular pressure (IOP), anterior segment and facial skin.ResultsThe OSDI score, MGYLS score and MGS score all improved from baseline to 1 month in both MiBoFlo and LipiFlow group, and these improvements were maintained at 2 months. CFS score, NIKBUT and MG loss had no significant change in both groups. CFS score improvement in MiBoFlo group were significantly more obvious than in LipiFlow group in the follow-up visit (p<0.01).ConclusionAs a portable and comfortable device, MiBoFlo treatment can offer an advancement for the treatment of MGD and a course of treatment results in at least two months of sustained improvement in both symptoms and meibomain gland function.

Download Full-text